Tetracyclic spirooxindole blockers of hNaV1.7: Activity in vitro and in CFA-induced inflammatory pain model
The structure-activity relationship of a new series of tetracyclic spirooxindoles led to the discovery of compound 25a, a potent hNaV1.7 blocker with improved ADME properties and in vivo efficacy in the CFA-induced inflammatory pain model.